Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-05-01T06:05:30.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.
    Difference
    0.0%
    Check dated 2025-04-23T22:49:18.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The webpage has been updated to include new eligibility criteria and study details for a clinical trial involving pembrolizumab and lenvatinib for non-small cell lung cancer, with specific focus on patient characteristics and outcomes. Additionally, the last update date has been changed to April 16, 2025.
    Difference
    65%
    Check dated 2025-04-16T16:44:14.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 4, 2025.
    Difference
    0.1%
    Check dated 2025-04-09T10:58:58.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:42:05.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page has updated its date references, removing older dates and adding new ones for March 2025.
    Difference
    0.2%
    Check dated 2025-03-11T04:51:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.